InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.080 0.05 (2.46%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,701 Positive Results From Phase 2 Lumbar Fusion Trial 21 Oct 2010 10:02AM $2.330 $2.080 fallen by 10.73%
$2,701 Angioblast Stockholders Approve Acquisition By Mesoblast 20 Oct 2010 10:32AM $2.340 $2.080 fallen by 11.11%
$2,701 Mesoblast Targets Broader Cancer Indications 14 Oct 2010 9:28AM $2.550 $2.080 fallen by 18.43%
$2,701 Response to an ASX Price Query 10 Sep 2010 2:44PM $2.280 $2.080 fallen by 8.77%
$2,701 Preliminary Final Report 26 Aug 2010 10:10AM $1.870 $2.080 risen by 11.23%
$2,701 On Track for Phase 3 BMT Trial After Positive FDA Meeting 16 Aug 2010 9:41AM $1.920 $2.080 risen by 8.33%
$2,701 Appendix 4C - quarterly 30 Jul 2010 2:55PM $2.530 $2.080 fallen by 17.79%
$2,701 TGA Approval To Commercially Manufacture Stem Cell Products 21 Jul 2010 10:02AM $1.900 $2.080 risen by 9.47%
$2,701 Phase 3 Meeting Set With FDA On Bone Marrow Regeneration 12 Jul 2010 9:14AM $1.740 $2.080 risen by 19.54%
$2,701 USA FDA Clears Phase 2 Trial For Cervical Spinal Fusion 19 May 2010 9:39AM $2.000 $2.080 risen by 4%
$2,701 Reinstatement to Official Quotation 12 May 2010 1:24PM $1.990 $2.080 risen by 4.52%
$2,701 Mesoblast To Acquire Angioblast Systems, 37M Capital Raising 12 May 2010 1:24PM $1.990 $2.080 risen by 4.52%
$2,701 Suspension from Official Quotation 5 May 2010 10:10AM $1.935 $2.080 risen by 7.49%
$2,701 Trading Halt 3 May 2010 9:37AM $1.935 $2.080 risen by 7.49%
$2,701 Appendix 4C and Clinical Trial Update 30 Apr 2010 2:11PM $1.990 $2.080 risen by 4.52%
$2,701 Market Exclusivity Strengthened by New USA Healthcare Act 6 Apr 2010 10:34AM $2.060 $2.080 risen by 0.97%
$2,701 Key Bone Repair Patent Granted in the United States 3 Mar 2010 9:11AM $1.940 $2.080 risen by 7.22%
$2,701 Half Yearly Report and Accounts 25 Feb 2010 10:19AM $1.950 $2.080 risen by 6.67%
$2,701 Appendix 4C - quarterly 29 Jan 2010 4:54PM $1.830 $2.080 risen by 13.66%
$2,701 Response to an ASX Price Query 11 Jan 2010 8:57AM $1.960 $2.080 risen by 6.12%
$2,701 Mesoblast - National Electronic Media Coverage 21 Dec 2009 10:38AM $1.350 $2.080 risen by 54.07%
$2,701 Cells Regenerate Pancreas and Reduce Diabetic Glucose Levels 18 Dec 2009 8:23AM $1.365 $2.080 risen by 52.38%
$2,701 Sustained 6 Month Improvement in Heart Muscle Function 18 Nov 2009 10:16AM $1.420 $2.080 risen by 46.48%
$2,701 Successful Bone Marrow Regeneration in Cancer Patients 6 Nov 2009 9:00AM $1.200 $2.080 risen by 73.33%
$2,701 Appendix 4C - quarterly 12 Oct 2009 10:41AM $1.045 $2.080 risen by 99.04%

1051 - 1075 of 1176 results

Page 43 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.